PT1268445E - Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular - Google Patents

Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular

Info

Publication number
PT1268445E
PT1268445E PT01914026T PT01914026T PT1268445E PT 1268445 E PT1268445 E PT 1268445E PT 01914026 T PT01914026 T PT 01914026T PT 01914026 T PT01914026 T PT 01914026T PT 1268445 E PT1268445 E PT 1268445E
Authority
PT
Portugal
Prior art keywords
sub
sup
alkyl
cyano
amino
Prior art date
Application number
PT01914026T
Other languages
English (en)
Portuguese (pt)
Inventor
Andrew Peter Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT1268445E publication Critical patent/PT1268445E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PT01914026T 2000-03-28 2001-03-23 Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular PT1268445E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0007371.8A GB0007371D0 (en) 2000-03-28 2000-03-28 Chemical compounds

Publications (1)

Publication Number Publication Date
PT1268445E true PT1268445E (pt) 2005-11-30

Family

ID=9888482

Family Applications (1)

Application Number Title Priority Date Filing Date
PT01914026T PT1268445E (pt) 2000-03-28 2001-03-23 Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular

Country Status (21)

Country Link
US (1) US6906065B2 (enExample)
EP (1) EP1268445B1 (enExample)
JP (1) JP2003528861A (enExample)
KR (1) KR100802367B1 (enExample)
CN (1) CN1231471C (enExample)
AT (1) ATE303366T1 (enExample)
AU (2) AU3941401A (enExample)
BR (1) BR0109577A (enExample)
CA (1) CA2399864A1 (enExample)
DE (1) DE60113080T2 (enExample)
DK (1) DK1268445T3 (enExample)
ES (1) ES2247078T3 (enExample)
GB (1) GB0007371D0 (enExample)
IL (2) IL151392A0 (enExample)
MX (1) MXPA02009255A (enExample)
MY (1) MY124527A (enExample)
NO (1) NO324228B1 (enExample)
NZ (1) NZ521032A (enExample)
PT (1) PT1268445E (enExample)
WO (1) WO2001072717A1 (enExample)
ZA (1) ZA200206957B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
US20030139435A1 (en) * 2001-06-26 2003-07-24 Gulzar Ahmed N-heterocyclic inhibitors of TNF-alpha expression
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003062246A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-thia-1,6,8-triaza-naphtalene-2,2-dioxides as cdk inhibitors
GB0205688D0 (en) * 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US7442697B2 (en) 2002-03-09 2008-10-28 Astrazeneca Ab 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
WO2006064251A1 (en) * 2004-12-17 2006-06-22 Astrazeneca Ab 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors
AU2006274733B2 (en) * 2005-07-30 2010-09-16 Astrazeneca Ab Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
BRPI0616722A2 (pt) 2005-09-30 2012-12-25 Astrazeneca Ab composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas
US7713987B2 (en) 2005-12-06 2010-05-11 Rigel Pharmaceuticals, Inc. Pyrimidine-2,4-diamines and their uses
PE20080068A1 (es) * 2006-05-15 2008-03-17 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2580320B1 (en) 2010-06-14 2018-08-01 The Scripps Research Institute Reprogramming of cells to a new fate
PH12013501940A1 (en) 2011-03-23 2015-12-04 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN111686113B (zh) * 2019-03-15 2022-12-30 北京大学 Sonic Hedgehog抑制剂及应用
CN112110863A (zh) * 2020-08-27 2020-12-22 中山大学 一种磺酰氟类化合物、其制备方法以及通过其制备磺酰胺类化合物的方法
CN117715904A (zh) 2021-05-07 2024-03-15 凯麦拉医疗公司 Cdk2降解剂和其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
PT664291E (pt) 1992-10-05 2000-11-30 Ube Industries Composto de pirimidina
JPH08503971A (ja) 1993-10-01 1996-04-30 チバ−ガイギー アクチェンゲゼルシャフト ピリミジンアミン誘導体及びその調製のための方法
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PT672042E (pt) 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
ES2167377T3 (es) 1993-10-01 2002-05-16 Novartis Ag Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
JP2000507558A (ja) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Cns損傷についての新規な治療
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
DE69839338T2 (de) * 1997-02-05 2008-07-10 Warner-Lambert Company Llc Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
PL199893B1 (pl) 1997-06-12 2008-11-28 Rhone Poulenc Rorer Ltd Imidazolilo-cykliczne acetale, kompozycja farmaceutyczna oraz zastosowanie imidazolilo-cyklicznych acetali
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2001515032A (ja) * 1997-08-15 2001-09-18 セフアロン・インコーポレーテツド 前立腺がんを治療するためのチロシンキナーゼ阻害剤と化学的去勢術の組み合わせ法
JP2001519345A (ja) 1997-10-02 2001-10-23 メルク エンド カムパニー インコーポレーテッド プレニルタンパク質トランスフェラーゼの阻害剤
AU9449398A (en) 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
ATE401312T1 (de) 1997-12-15 2008-08-15 Astellas Pharma Inc Pyrimidin-5-carboxamid-derivate
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
EP1245567B1 (en) 1998-03-27 2011-03-02 Janssen Pharmaceutica NV HIV inhibiting pyrimidine derivatives
GB9806739D0 (en) 1998-03-28 1998-05-27 Univ Newcastle Ventures Ltd Cyclin dependent kinase inhibitors
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
TR200101186T2 (tr) 1998-09-18 2001-10-22 Basf Aktiengesellschaft Protein kinaz engelleyiciler olarak pyrrolopyrimidin'ler
DE69928414T2 (de) 1998-09-18 2006-08-03 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidine als kinaseinhibitoren
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
EP1126843A4 (en) 1998-10-29 2005-06-15 Bristol Myers Squibb Co AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
BR0007919A (pt) 1999-02-01 2002-04-09 Cv Therapeutics Inc Composição purina 2,6,9-trisubstituìda
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1224185B1 (en) 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
KR20020050294A (ko) 1999-11-22 2002-06-26 피터 기딩스 신규화합물
JP2003519143A (ja) 1999-12-28 2003-06-17 ファーマコピーア,インコーポレーティッド ピリミジン及びトリアジン系キナーゼ阻害剤
CA2400447C (en) 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
US6906065B2 (en) 2005-06-14
GB0007371D0 (en) 2000-05-17
US20030087923A1 (en) 2003-05-08
DE60113080T2 (de) 2006-05-18
EP1268445A1 (en) 2003-01-02
CN1419548A (zh) 2003-05-21
CA2399864A1 (en) 2001-10-04
DK1268445T3 (da) 2005-11-07
MY124527A (en) 2006-06-30
KR100802367B1 (ko) 2008-02-13
NZ521032A (en) 2004-05-28
IL151392A0 (en) 2003-04-10
NO20024644L (no) 2002-11-27
JP2003528861A (ja) 2003-09-30
AU3941401A (en) 2001-10-08
CN1231471C (zh) 2005-12-14
AU2001239414B2 (en) 2004-09-02
ES2247078T3 (es) 2006-03-01
BR0109577A (pt) 2003-01-28
ZA200206957B (en) 2003-12-01
EP1268445B1 (en) 2005-08-31
NO324228B1 (no) 2007-09-10
KR20020083532A (ko) 2002-11-02
MXPA02009255A (es) 2003-03-12
NO20024644D0 (no) 2002-09-27
WO2001072717A1 (en) 2001-10-04
ATE303366T1 (de) 2005-09-15
DE60113080D1 (de) 2005-10-06
IL151392A (en) 2007-06-17

Similar Documents

Publication Publication Date Title
PT1268445E (pt) Derivados de 4-amino-5-ciano-2-anilino-pirimidina e sua utilizacao como inibidores de cinases do ciclo celular
EA200501009A1 (ru) Замещённые пирролопиразольные производные в качестве ингибиторов киназы
PL372799A1 (en) New compounds
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
FI950156A0 (fi) Dihydropyratsolopyrroleja
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
EA200400361A1 (ru) Производные алкинарилнафтиридин-4(1h)-онов в качестве ингибитора фосфодиэстеразы типа iv
SE0202463D0 (sv) Novel compounds
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
ATE259813T1 (de) Triazolopyrimidinderivate
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
MXPA03000887A (es) Derivados heterociclicos fusionados como inhibidores de fosfodiesterasa.
DE602004015628D1 (de) Imidazopyridinderivate als induzierbare no-synthaseinhibitoren
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
NO20042729L (no) Heksasykliske forbindelser
NO20010626D0 (no) N-substituerte azabicykloheptanderivater, deres fremstilling og anvendelse
BR0107405A (pt) Derivados de indol que atuam como antagonistas do receptor mcp-1
ES2166710A1 (es) Nuevos compuestos heterociclicos con actividad antiinflamatoria.
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla
WO2002067866A3 (en) Piperazine derivatives as metalloprotease inhibitors